Info

Functional Genetics, Inc. (FGI) uses novel technologies to develop new therapeutics for infectious disease and to improve the quality and efficiency of biologics-based drugs. Our Random Homozygous Gene Perturbation (RHGP) technology combines molecular biology and functional understanding of cell behavior to find elegant solutions to complex biological problems. We have demonstrated that RHGP can provide practical answers that rapidly translate into new drugs and enhance existing therapeutics. The results are better drugs, based on fundamental understanding of medical challenges, and produced at a lower cost. We believe RHGP technology allows us to identify and prosecute therapeutic targets much more efficiently than existing approaches. Two current methods are predominantly used to evaluate new drug targets: (1) genomic or proteomic sampling of diseased tissues and (2) broad-based screening of chemical libraries. Sampling approaches often yield vast number of targets, but the correlative nature of the results may not translate into practical applications. On the other hand, library screening may identify compounds without any indication of the target, toxicity or mechanism. In an era where the development costs of a single drug exceed $1 billion and regulatory agencies place increasing emphasis on the mechanistic understanding, neither approach is optimal.